The Specific Copper(II) Chelator TDMQ20 Is Efficient for the Treatment of Wilson’s Disease in Mice
(1) Background: In patients with Wilson’s disease, the deficiency of the copper carrier ATP7B causes the accumulation of copper in the liver, brain and various other organs. Lifelong treatment is therefore mandatory, using copper chelators to increase the excretion of copper and to avoid life-threat...
Main Authors: | Yingshan Zhu, Ying Tang, Lan Huang, Michel Nguyen, Yan Liu, Anne Robert, Bernard Meunier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/12/2719 |
Similar Items
-
Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer’s Disease
by: Lan Huang, et al.
Published: (2022-12-01) -
Benefits and drawbacks of current copper chelators in Wilson disease
by: Ioan-Cristian Lupescu, et al.
Published: (2023-03-01) -
Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers
by: Martin Hruby, et al.
Published: (2021-11-01) -
Wilson’s disease
by: Hursitoglu Mehmet, et al.
Published: (2010-04-01) -
Hyaluronate/black phosphorus complexes as a copper chelating agent for Wilson disease treatment
by: Seong-Jong Kim, et al.
Published: (2021-06-01)